Susan J. Hayflick, Chris Andon, Antoinette D. I. van Asselt, Harm Jan Hektor, Ody Sibon
Springer Nature ·
2026-11-16
· DOI 10.1038/s41582-026-01295-8
Аннотация
Nature Reviews Neurology, Published online: 16 November 2026; doi:10.1038/s41582-026-01295-8 The traditional for-profit model of drug development is not sustainable for rare and ultra-rare neurological conditions, so alternative models are needed. Here, we consider some of the programmes and initiatives that are providing viable pathways.
Susan J. Hayflick, Chris Andon, Antoinette D. I. van Asselt, Harm Jan Hektor, Ody Sibon. Drug development models for ultra-rare disorders. // Nature Reviews Neurology. – 2026. – DOI: 10.1038/s41582-026-01295-8. – URL: https://www.nature.com/articles/s41582-026-01295-8
Susan J. Hayflick, Chris Andon, Antoinette D. I. van Asselt, Harm Jan Hektor, & Ody Sibon (2026). Drug development models for ultra-rare disorders. Nature Reviews Neurology. https://doi.org/10.1038/s41582-026-01295-8
Susan J. Hayflick, et al. “Drug development models for ultra-rare disorders.” Nature Reviews Neurology, 2026. doi:10.1038/s41582-026-01295-8.
@article{Hayflick2026,
title = {Drug development models for ultra-rare disorders},
author = {Hayflick, Susan J. and Andon, Chris and Asselt, Antoinette D. I. van and Hektor, Harm Jan and Sibon, Ody},
journal = {Nature Reviews Neurology},
year = {2026},
doi = {10.1038/s41582-026-01295-8},
url = {https://www.nature.com/articles/s41582-026-01295-8}
}